ES2187047T3 - Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular. - Google Patents
Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.Info
- Publication number
- ES2187047T3 ES2187047T3 ES98938555T ES98938555T ES2187047T3 ES 2187047 T3 ES2187047 T3 ES 2187047T3 ES 98938555 T ES98938555 T ES 98938555T ES 98938555 T ES98938555 T ES 98938555T ES 2187047 T3 ES2187047 T3 ES 2187047T3
- Authority
- ES
- Spain
- Prior art keywords
- dna
- composition
- animal
- regulation
- relates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000020129 regulation of cell death Effects 0.000 title abstract 2
- 230000025053 regulation of cell proliferation Effects 0.000 title abstract 2
- 108020000946 Bacterial DNA Proteins 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a una composición y a un procedimiento que permite, en los organismos pluricelulares, la regulación de la proliferación y la muerte de las células. La presente invención se refiere también a una composición que comprende ADN bacteriano (ADN-B) y un primer vehículo farmacéuticamente aceptable, induciendo el ADN-B una respuesta en las células receptivas de un animal. La presente invención se refiere más en particular a una composición que comprende ADN micobacteriano (ADN-M) y un primer vehículo farmacéuticamente aceptable, en la que el ADN-M inhibe la proliferación de las células receptivas de un animal, induce la apoptosis en las células receptivas de un animal, y estimula las células receptivas del sistema inmunitario del animal para que produzcan moléculas bioactivas. Se describen también procedimientos de fabricación de la composición de ADN-M, y procedimientos de utilización de esta composición de ADN-M.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5477797P | 1997-08-05 | 1997-08-05 | |
| US7506798P | 1998-02-18 | 1998-02-18 | |
| US7511198P | 1998-02-18 | 1998-02-18 | |
| US8631798P | 1998-05-21 | 1998-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2187047T3 true ES2187047T3 (es) | 2003-05-16 |
Family
ID=27489673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98938555T Expired - Lifetime ES2187047T3 (es) | 1997-08-05 | 1998-08-05 | Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6326357B1 (es) |
| EP (1) | EP1003525B1 (es) |
| JP (2) | JP4335435B2 (es) |
| KR (1) | KR100533576B1 (es) |
| AT (1) | ATE227996T1 (es) |
| AU (1) | AU736450B2 (es) |
| BR (1) | BR9815602A (es) |
| CA (1) | CA2299548C (es) |
| DE (1) | DE69809561T2 (es) |
| DK (1) | DK1003525T3 (es) |
| ES (1) | ES2187047T3 (es) |
| HU (1) | HU227921B1 (es) |
| IL (3) | IL134371A0 (es) |
| NO (1) | NO322450B1 (es) |
| NZ (1) | NZ502674A (es) |
| PT (1) | PT1003525E (es) |
| WO (1) | WO1999007383A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4335435B2 (ja) | 1997-08-05 | 2009-09-30 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | 細胞増殖および細胞死を調節する組成物および方法 |
| DE69829316T2 (de) * | 1998-02-18 | 2006-04-13 | Bioniche Life Sciences Inc., Belleville | Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand |
| US6809081B1 (en) | 1998-12-04 | 2004-10-26 | Bioniche Life Sciences, Inc. | Chemotherapeutic composition and method |
| CA2353905C (en) * | 1998-12-04 | 2010-06-22 | Nigel C. Phillips | Chemotherapeutic composition and method |
| JP4488626B2 (ja) * | 1998-12-04 | 2010-06-23 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | 炎症の治療法 |
| US6794368B1 (en) * | 1999-04-01 | 2004-09-21 | Bioniche Life Sciences Inc. | Composition and method for inducing apoptosis in prostate cancer cells |
| PT1165106E (pt) * | 1999-04-01 | 2005-10-31 | Bioniche Life Sciences Inc | Composicoes e metodo para induzir apoptose em celulas de cancro da prostata, por m-adn e mcc |
| EP1181304B1 (en) | 1999-04-08 | 2007-10-10 | Antisoma Research Limited | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| WO2001022979A1 (en) * | 1999-09-29 | 2001-04-05 | Bioniche Life Sciences Inc. | Method to disrupt mitochondrial function |
| AU785212B2 (en) * | 1999-12-13 | 2006-11-09 | Bioniche Life Sciences Inc. | Therapeutically useful synthetic oligonucleotides |
| WO2001047561A1 (en) * | 1999-12-28 | 2001-07-05 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
| US20030044352A1 (en) * | 2001-04-24 | 2003-03-06 | Phillips Nigel C. | Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls |
| US6673566B1 (en) | 2002-01-10 | 2004-01-06 | The United States Of America As Represented By The Secretary Of Agriculture | Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes |
| WO2008012528A1 (en) * | 2006-07-25 | 2008-01-31 | Lipoxen Technologies Limited | N-terminal polysialylation |
| BR112013008727A2 (pt) | 2010-10-13 | 2016-06-28 | Bioniche Urology Ip Inc | composições de parede celular de ácido ribonucleico micobacteriano e métodos de fabricação e uso das mesmas |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172815A (en) | 1962-04-24 | 1965-03-09 | Warner Lambert Pharmaceutical | Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof |
| FR2160326B1 (es) | 1971-11-19 | 1975-02-07 | Anvar | |
| US4152423A (en) | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
| CH602920A5 (es) | 1973-02-23 | 1978-08-15 | Wellcome Found | |
| US3976544A (en) | 1973-06-19 | 1976-08-24 | The Agence Nationale De Valorisation De Le Recherche | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction |
| FR2374042A1 (fr) | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
| JPS54140710A (en) | 1978-03-10 | 1979-11-01 | Mitsui Toatsu Chem Inc | Anti-tumor substance and its preparation |
| DE3011461C2 (de) | 1980-03-25 | 1986-10-30 | Dr. Madaus & Co, 5000 Köln | Verwendung von Propionibakterien |
| US4520019A (en) | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4579941A (en) | 1982-08-13 | 1986-04-01 | Mitsuitoatsu Chemicals, Inc. | Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent |
| US4663306A (en) | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| GB8404280D0 (en) | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
| US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| WO1994016727A1 (en) | 1993-01-29 | 1994-08-04 | Vetrepharm, Inc. | Immunotherapeutic composition |
| JP4335435B2 (ja) | 1997-08-05 | 2009-09-30 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | 細胞増殖および細胞死を調節する組成物および方法 |
-
1998
- 1998-08-05 JP JP2000506973A patent/JP4335435B2/ja not_active Expired - Fee Related
- 1998-08-05 HU HU0003012A patent/HU227921B1/hu not_active IP Right Cessation
- 1998-08-05 CA CA002299548A patent/CA2299548C/en not_active Expired - Fee Related
- 1998-08-05 PT PT98938555T patent/PT1003525E/pt unknown
- 1998-08-05 AU AU87236/98A patent/AU736450B2/en not_active Ceased
- 1998-08-05 DE DE69809561T patent/DE69809561T2/de not_active Expired - Lifetime
- 1998-08-05 WO PCT/CA1998/000744 patent/WO1999007383A1/en not_active Ceased
- 1998-08-05 EP EP98938555A patent/EP1003525B1/en not_active Expired - Lifetime
- 1998-08-05 ES ES98938555T patent/ES2187047T3/es not_active Expired - Lifetime
- 1998-08-05 NZ NZ502674A patent/NZ502674A/en not_active IP Right Cessation
- 1998-08-05 KR KR10-2000-7001237A patent/KR100533576B1/ko not_active Expired - Fee Related
- 1998-08-05 US US09/129,312 patent/US6326357B1/en not_active Expired - Lifetime
- 1998-08-05 IL IL13437198A patent/IL134371A0/xx active IP Right Grant
- 1998-08-05 AT AT98938555T patent/ATE227996T1/de active
- 1998-08-05 DK DK98938555T patent/DK1003525T3/da active
- 1998-08-05 US US09/129,313 patent/US6329347B1/en not_active Expired - Lifetime
- 1998-08-05 BR BR9815602-0A patent/BR9815602A/pt not_active Application Discontinuation
-
2000
- 2000-02-03 IL IL134371A patent/IL134371A/en not_active IP Right Cessation
- 2000-02-04 NO NO20000576A patent/NO322450B1/no not_active IP Right Cessation
-
2007
- 2007-01-24 IL IL180924A patent/IL180924A/en not_active IP Right Cessation
-
2008
- 2008-05-12 JP JP2008124958A patent/JP2008208140A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP4335435B2 (ja) | 2009-09-30 |
| HUP0003012A3 (en) | 2004-03-29 |
| DE69809561D1 (de) | 2003-01-02 |
| IL180924A0 (en) | 2007-07-04 |
| DK1003525T3 (da) | 2003-03-24 |
| EP1003525B1 (en) | 2002-11-20 |
| ATE227996T1 (de) | 2002-12-15 |
| NO20000576L (no) | 2000-04-04 |
| NO322450B1 (no) | 2006-10-09 |
| JP2001513504A (ja) | 2001-09-04 |
| NZ502674A (en) | 2002-06-28 |
| NO20000576D0 (no) | 2000-02-04 |
| AU736450B2 (en) | 2001-07-26 |
| WO1999007383A1 (en) | 1999-02-18 |
| CA2299548C (en) | 2009-12-29 |
| WO1999007383B1 (en) | 1999-03-25 |
| CA2299548A1 (en) | 1999-02-18 |
| HU227921B1 (hu) | 2012-06-28 |
| DE69809561T2 (de) | 2003-09-25 |
| PT1003525E (pt) | 2003-03-31 |
| US6329347B1 (en) | 2001-12-11 |
| IL180924A (en) | 2010-11-30 |
| EP1003525A1 (en) | 2000-05-31 |
| IL134371A0 (en) | 2001-04-30 |
| KR20010022643A (ko) | 2001-03-26 |
| US6326357B1 (en) | 2001-12-04 |
| AU8723698A (en) | 1999-03-01 |
| BR9815602A (pt) | 2001-12-11 |
| KR100533576B1 (ko) | 2005-12-05 |
| JP2008208140A (ja) | 2008-09-11 |
| IL134371A (en) | 2007-07-24 |
| HUP0003012A2 (hu) | 2000-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2187047T3 (es) | Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular. | |
| CY1119742T1 (el) | Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου | |
| ES2173314T3 (es) | Metodos y composiciones para la modificacion selectiva de acidos nucleicos. | |
| AR010348A1 (es) | Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen | |
| BR9808068A (pt) | Processo in vitro para eliminar células tumorosas de uma população de células que inclui células não-tumorosas, para enriquecerr o número de células germinativas numa população de células hematopoéticas, para preparar células hematopoéticas isoladas para reintrodução num paciente, para a eliminação de uma primeira população de células de uma segunda população de células, e, processo de eliminação de células tumorosas de uma população de células que inclui células não-tumorosas | |
| ES2162284T3 (es) | Proceso para la fabricacion de tensioactivos que contienen grupos alquilo de cadena ramificada. | |
| MX9705954A (es) | Formulaciones y metodos para reducir irritacion de la piel. | |
| ES2196181T3 (es) | Derivados de purina y proceso para su preparacion. | |
| EP1411118A4 (en) | Cell proliferation inhibitors with anti-glycanic-3 antibody | |
| ES2193145T3 (es) | Proteinas procoagulants quimericas. | |
| DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
| ES2060947T3 (es) | Un nuevo sistema de suministro de anticuerpos para modificadores de la respuesta biologica. | |
| NO331101B1 (no) | In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet. | |
| CO5011082A1 (es) | Formulacion medicamentosa con liberacion controlada de sus- tancia activa | |
| ES2144507T3 (es) | Potencializador de la actividad pesticida de bacillus. | |
| DK1900811T3 (da) | Berigede cellepopulationer i centralnervesystemet | |
| BRPI0518579A2 (pt) | mÉtodo para aumentar a atividade de cÉlula exterminadora natural em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, uso da composiÇço que compreende Ácido lipàico, e, mÉtodo para aumentar a resposta imune em um animal | |
| CY1105439T1 (el) | Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση | |
| Kashket et al. | Accumulation of methylglyoxal in the gingival crevicular fluid of chronic periodontitis patients | |
| DE69732857D1 (de) | Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen | |
| AR017190A1 (es) | Metodo para mejorar la resistencia o tolerancia a patogenos en una planta que comprende integrar en el genoma de dicha planta un gen que codificauna proteina de fusion que comprende una primer y segunda proteina o dominio de proteina con actividad antipatogenica, molecula de adn, su uso, proteinade | |
| AR014528A1 (es) | Adn que comprende una secuencia de nucleotidos que se puede traducir a una proteina con actividad de invertasa, proteina derivada del adn que tieneactividad de invertasa pero que carece de actividad beta-fructofuranosidasa; metodo para producir adn y dicho metodo donde el adn es producido por una | |
| ES2052482T1 (es) | Inhibidora de la proliferacion de celulas endoteliales. | |
| ECSP024267A (es) | Imidazotriazinonas sustituidas por 2-fenilo | |
| ES2166447T3 (es) | Acrilonitrilos diheterociclicos como inhibidores de la proliferacion de las celulas de la musculatura lisa. |